Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00387608 · ClinicalTrials.gov registry record · Phase 1
ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer
A Phase 1 study of Lymphoma and Leukemia, sponsored by National Institutes of Health Clinical Center (CC).
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT00387608: Completed Phase 1 study of Lymphoma and Leukemia, sponsored by National Institutes of Health Clinical Center (CC).
NCT00387608 is a Phase 1 study of Lymphoma and Leukemia that has completed, run by National Institutes of Health Clinical Center (CC). The registered enrollment target is 23 participants, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00387608, a Phase 1 study of Lymphoma and Leukemia, has completed, sponsored by National Institutes of Health Clinical Center (CC).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: ABT-888 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about the ways a patient's body handles the drug. PURPOSE: This early phase I trial is studying the side effects and best dose of ABT-888 in patients with refractory solid tumors or hematologic cancer.
Conditions Studied
Interventions
- PROCEDURE biopsy
- OTHER pharmacological study
- DRUG veliparib
Study Locations (1)
Maryland
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
What the finished NCT00387608 record still lists
NCT00387608 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 484-participant average among 299 other Lymphoma trials with a reported enrollment target (95% lower).
The record links to 3 conditions, with Lymphoma appearing as the primary indexed condition, and to 3 interventions - of which biopsy is the first listed.
NCT00387608 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00387608 about?
NCT00387608 is a clinical study titled "ABT-888 in Patients With Refractory Solid Tumors or Hematologic Cancer". RATIONALE: ABT-888 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Collecting and storing samples of blood from patients with cancer to study in the laboratory may help doctors learn more about the ways a patient's body handles the drug. PURPOSE: This ear...
What is the current status of trial NCT00387608?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2006-06. Estimated completion is 2009-04.
What conditions does trial NCT00387608 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Unspecified Adult Solid Tumor, Protocol Specific.
What interventions are being tested in trial NCT00387608?
The interventions under investigation include: biopsy (PROCEDURE), pharmacological study (OTHER), veliparib (DRUG).
Who is sponsoring clinical trial NCT00387608?
This trial is sponsored by National Institutes of Health Clinical Center (CC), which has 338 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00387608 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00387608's enrollment target sits among peer trials
23 240th of 299 higher than 58 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
RECRUITING · Phase 1
-
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
RECRUITING · Phase 1
-
CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies
RECRUITING · Phase 1
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
RECRUITING · Phase 1
-
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia